Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 RON | -2.45% | -4.79% | +8.90% |
1st Jan change | Capi. | |
---|---|---|
+8.90% | 482M | |
+21.28% | 44.4B | |
+24.60% | 23.03B | |
+19.22% | 15.14B | |
+12.87% | 13.12B | |
+44.67% | 11.85B | |
-8.33% | 6.99B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.22% | 5.52B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology